Deutsche Bank’s Grace Therapeutics GRCE Stock Holding History

Deutsche Bank’s Portfolio GRCE Stock Details GRCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-1,619	Closed	-$190K	–	4901
2019 Q4	$190K	Buy	+1,619	New	+$160K	﹤0.01%	3258
2019 Q3	–	Sell	-130	Closed	-$7K	–	5338
2019 Q2	$7K	Sell	130 -380	-75%	-$16.7K	﹤0.01%	5049
2019 Q1	$24K	Buy	+510	New	+$25.2K	﹤0.01%	4754
2018 Q1	–	Sell	-5,263	Closed	-$238K	–	5639
2017 Q4	$238K	Buy	+5,263	New	+$354K	﹤0.01%	3953
2016 Q1	–	Sell	-4	Closed	–	–	5367
2015 Q4	$0	Buy	+4	New	+$472	﹤0.01%	5438
2015 Q1	–	Sell	-3	Closed	–	–	6078
2014 Q4	$0	Buy	+3	New	+$738	﹤0.01%	6346

Other funds holding GRCE

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

Oppenheimer & Co New York $8.21B AUM 28.81% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

JLBC

J.L. Bainbridge & Co Sarasota, Florida $1.27B AUM 26.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

SIG

Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return

Deutsche Bank's GRCE Position: Q1 2020 in Review

Deutsche Bank sold out of Grace Therapeutics (GRCE) in Q1 2020, closing a stake of 1,619 shares — an estimated $190K sold.

Deutsche Bank first reported a position in GRCE in Q4 2014 and held it in 6 quarters. The position peaked at $238K in Q4 2017. 26 funds tracked by Wall St. Rank hold GRCE as of Q1 2020.

Deutsche Bank reported no remaining Grace Therapeutics position as of Q1 2020 after selling out during the quarter.
Deutsche Bank sold 1,619 Grace Therapeutics shares in Q1 2020, an estimated $190K.
Deutsche Bank first reported a position in Grace Therapeutics in Q4 2014 and held it in 6 quarters.
Deutsche Bank's Grace Therapeutics position peaked at $238K in Q4 2017.
26 funds tracked by Wall St. Rank held Grace Therapeutics as of Q1 2020.

Based on Deutsche Bank's 13F filing for Q1 2020, filed 14 May 2020.